<DOC>
	<DOC>NCT02511379</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Systane® Balance following 90 days of QID (4 times/day) dosing among Indian subjects with dry eye. This study will be conducted in India.</brief_summary>
	<brief_title>Clinical Evaluation of Systane® Balance in Dry Eye Subjects</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Sign informed consent and willing and able to attend all study visits; Dry eye in both eyes diagnosed by an ophthalmologist; Other protocolspecified inclusion criteria may apply. Women of childbearing potential who are pregnant or breastfeeding; Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in the study; Ocular surgery or ocular trauma requiring medical or pharmacological treatment within 1 year of Screening; Use of topical ocular prescription or nonprescription medications, RESTASIS or topical ocular steroids within 14 days of Screening; Use of any artificial tears/gels/lubricants/rewetting drops within 4 hours of Screening; Contact lens wear within 1 week of Screening and/or unwillingness to discontinue contact lens wear for the duration of the study; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>